[Wendy Beltrami]

Mar. 12, 2008
Amgen Statement on Successful Outcome of Romiplostim Panel Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--March 12, 2008--Amgen Inc. (NASDAQ:AMGN) today issued the following statement on the outcome of the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting on romiplostim, a investigational thrombopoietin mimetic peptibody, for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

"We are pleased that the panel today recognized the importance of this therapeutic advance and unanimously voted to recommend approval of the romiplostim application. We believe that this product has the potential to be an important new treatment option for the orphan population of adult patients suffering from chronic ITP. Patients with chronic ITP, a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia) face the risk of bleeding events due to low platelet counts.

"We look forward to continued productive discussions with the FDA. We strongly believe the data contained in our registrational clinical studies paired with the proposed comprehensive risk management program support approval by the FDA in the second quarter of this year."